Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.21B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
AAPG Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Ascentage Pharma Group InternationalNASDAQ: AAPG
Net Margin · Q4 FY2025 · quarter ended Dec 2025
Net margin widens to -191.5%
Net margin was -191.5% in Q4 FY2025, up 170.8 pp from a year earlier. Over 3 fiscal years it widened by 204.6 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 7 analysts of -39.0% for the fiscal year ending Dec 2026, up from -216.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -191.5%— QoQ
- Last fiscal yearDec 2025
- -216.5%-175.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +170.8 pp | — | — |
| 1 year | -175.1 pp | +177.5 pp | +352.6 pp |
| 3 years | +204.6 pp | +210.1 pp | +5.6 pp |
| 5 years | +226.4 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -216.5%
- Year-over-year change
- -175.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -216.5% | -175.1pp |
| FY2024 | 2024-12-31 | -41.3% | +375.6pp |
| FY2023 | 2023-12-31 | -417.0% | +4.0pp |
| FY2022 | 2022-12-31 | -421.0% | +2382.4pp |
| FY2021 | 2021-12-31 | -2803.4% | — |
Net Margin vs competitors
How AAPG compares with its peers on the latest reported figures
- AAPG's FY2025 net margin of -216.5% is the 6th highest of the 9 companies compared; the peer median is -125.5%.
- Its year-over-year change of -175.1 pp is the lowest of 8, against a peer median of +334.5 pp.
- Over three fiscal years its change of +204.6 pp compares with a peer median of +160.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 42.0% | +334.5 pp | +152.0 pp | |
| LTM Jun 2026 | -41.9% | +7.8 pp | +168.0 pp | |
| LTM Mar 2026 | -62.2% | +4313.7 pp | +63.2 pp | |
| LTM Jun 2026 | -88.2% | +1325.2 pp | — | |
| FY2025 | -162.9% | +146.9 pp | +272.3 pp | |
AAPGAscentage Pharma Group International | FY2025 | -216.5% | -175.1 pp | +204.6 pp |
| LTM Mar 2026 | -297.8% | -38.2 pp | +120.1 pp | |
| LTM Mar 2026 | -391.2% | +1097.6 pp | +2165.7 pp | |
| LTM Jun 2024 | -833.1% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding AAPG) | -125.5% | +334.5 pp | +160.0 pp | |
Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.91M | 209.71M | 221.98M | 980.65M | 558.48M |
| Cost of Revenue | 3.33M | 22M | 30.54M | 29.09M | 131.73M |
| Gross Profit | 24.58M | 187.71M | 191.44M | 951.57M | 426.75M |
| Gross Margin | 88.1% | 89.5% | 86.2% | 97.0% | 76.4% |
| Research & Development | 766.49M | 743.1M | 706.97M | 947.25M | 1.08B |
| Selling, General & Admin | 191.26M | 328.02M | 376.46M | 383.12M | 522.67M |
| Operating Expenses | 957.75M | 1.04B | 1.06B | 1.32B | 1.61B |
| Depreciation & Amortization | 17.18M | 47.42M | 93.2M | 93.17M | 84.12M |
| EBITDA | (798.34M) | (786.97M) | (743.61M) | (237.63M) | (1.1B) |
| EBITDA Margin | -2860.4% | -375.3% | -335.0% | -24.2% | -196.1% |
| Operating Income | (869.84M) | (849.81M) | (872.64M) | (369.73M) | (1.18B) |
| Operating Margin | -3116.6% | -405.2% | -393.1% | -37.7% | -211.1% |
| Interest Income | 7.11M | 9.73M | 32.41M | 37.84M | 79.89M |
| Interest Expense | 16.73M | 52.79M | 96.06M | 64.46M | 52.6M |
| Other Income / Expenses | 37.59M | (37.36M) | (60.23M) | (25.53M) | (23.21M) |
| Income Before Tax | (832.25M) | (887.17M) | (932.86M) | (395.26M) | (1.2B) |
| Pre-Tax Margin | -2981.9% | -423.0% | -420.2% | -40.3% | -215.3% |
| Income Tax Expense | (49.83M) | (4.25M) | (7.15M) | 10.43M | 6.75M |
| Net Income | (782.42M) | (882.92M) | (925.64M) | (405.43M) | (1.21B) |
| Net Margin | -2803.4% | -421.0% | -417.0% | -41.3% | -216.5% |
| EPS (Basic) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| EPS (Diluted) | (49.12) | (53.60) | (52.48) | (5.36) | (13.56) |
| Weighted Avg Shares | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
| Weighted Avg Shares (Diluted) | 15.91M | 16.48M | 17.64M | 75.52M | 89.03M |
Ascentage Pharma Group International
NASDAQ:AAPG
Intrinsic Alpha fair value
Locked
Current Price
$13.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.